Skip to Navigation Skip to Search Skip to Content
Search All Centers

Myelofibrosis Clinical Trial Update: The Science Behind JAK Inhibitors

Published on October 20, 2017

With the knowledge clinicians are gaining about the driver mutations of myeloproliferative neoplasms (MPNs), JAK inhibitors have become more recognized as a personalized, targeted therapy. But how do JAK inhibitors actually work? Dr. David Snyder from City of Hope explains what these medicines actual inhibit and goes on to discuss different variations of JAK inhibitors. Dr. Snyder shares information about approved JAK inhibitors and others in clinical trials, such as the PAC203 trial for pacritinib.

To find open clinical trial sites for the PAC203 clinical trial, click here.

Sponsorship of this program was provided by CTI BioPharma.

Featuring

You might also like